According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an overweight rating on the stock in a report on Thursday, August 11th. Citigroup Inc. lifted their target price on shares of Atyr Pharma from $3.00 to $4.00 and gave the stock a neutral rating in a report on Tuesday, August 16th. Finally, BMO Capital Markets set a $8.00 target price on shares of Atyr Pharma and gave the stock a hold rating in a report on Thursday, October 6th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $6.50.
Shares of Atyr Pharma (NASDAQ:LIFE) opened at 2.78 on Wednesday. The stock’s 50 day moving average price is $3.10 and its 200-day moving average price is $3.22. The company’s market cap is $65.94 million. Atyr Pharma has a 12-month low of $2.48 and a 12-month high of $13.26.
Atyr Pharma (NASDAQ:LIFE) last announced its earnings results on Wednesday, August 10th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.06. On average, equities research analysts forecast that Atyr Pharma will post ($2.56) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of LIFE. A.R.T. Advisors LLC boosted its stake in Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock worth $108,000 after buying an additional 18,410 shares during the last quarter. Bridgeway Capital Management Inc. acquired a new stake in Atyr Pharma during the second quarter worth $133,000. BlackRock Institutional Trust Company N.A. boosted its stake in Atyr Pharma by 317.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 344,214 shares of the company’s stock worth $957,000 after buying an additional 261,753 shares during the last quarter. BlackRock Advisors LLC boosted its stake in Atyr Pharma by 14,820.9% in the second quarter. BlackRock Advisors LLC now owns 244,405 shares of the company’s stock worth $679,000 after buying an additional 242,767 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Atyr Pharma by 120.3% in the second quarter. Vanguard Group Inc. now owns 439,732 shares of the company’s stock worth $1,223,000 after buying an additional 240,101 shares during the last quarter. 44.75% of the stock is currently owned by institutional investors and hedge funds.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.